Does early initiation of non-statin therapy, evolocumab with LDL-C <50mg/dL contribute to the reduction of hospital readmissions in patients with ACS?: a single center real world evidence from ELAINE
4 April 2025 (09:00 - 18:00)
Organised by: 
Abstract
Slides
About the speaker
Tufts University School of Medicine, Boston (United States of America)
77 More presentations in this session
Doctor A. Wahab (Leeds, GB)
Professor D. Malidze (Tbilisi, GE)
Access the full session
The Event
ESC Preventive Cardiology 2025
4 April 2025
09:00 CET
